[Live trading account: ¥9.24M; +¥0.4M today] Last night, the Federal Reserve released minutes from its latest interest-rate meeting; Moderna’s global first mRNA cancer vaccine achieves Phase III success.

【Answer 1】 First, it outperformed the ‘gold standard’—Keytruda. Keytruda, Merck’s blockbuster drug, consistently ranks among the world’s top-selling pharmaceuticals and serves as the standard-of-care adjuvant therapy for high-risk melanoma patients following surgery. For decades, virtually no regimen has demonstrated a significantly greater ability than Keytruda monotherapy to extend recurrence-free survival in the adjuvant setting. The combination of intismeran plus Keytruda, however, achieved precisely that. Earlier Phase II data had already delivered encouraging signals: this combination reduced the risk of recurrence or death by 49% (HR = 0.51); five-year follow-up results presented at ASCO 2026 showed a continued 59% reduction in the risk of distant metastasis or death (HR = 0.411). The Phase III trial enrolled 1,137 patients with high-risk melanoma who had undergone complete surgical resection—and its results corroborated earlier Phase II findings. Second, it validates the feasibility of mRNA technology in cancer therapeutics. This is not a preventive vaccine like those developed for COVID-19, but rather a comprehensive therapeutic platform built on ‘tumor sequencing → neoantigen prediction → personalized mRNA design → precise immune activation’. In plain terms: after surgically removing a patient’s tumor, clinicians obtain a tissue sample for genomic sequencing to identify the tumor’s unique mutational signature—essentially mapping the cancer cell’s ‘face’. Then, using mRNA technology, these mutations are encoded into a molecular ‘wanted poster’, with each vaccine capable of targeting up to 34 neoantigens. Once injected, the vaccine trains the patient’s T cells to recognize and eliminate cells bearing these cancer-specific markers. Traditional chemotherapy operates on a ‘scorched-earth’ principle—indiscriminately attacking all rapidly dividing cells. While cancer cells are harmed, so too are hair follicles and hematopoietic cells, resulting in side effects such as hair loss and immunosuppression—a classic ‘lose 1,000 enemies, sacrifice 800 of our own’. In contrast, mRNA cancer vaccines pursue an alternative path: precise identification and targeted elimination. One major reason cancer is so difficult to treat is its extraordinary ability to evade immune detection—immune cells often simply fail to recognize it as foreign. Neoantigen vaccines address this by proactively ‘exposing’ the most distinctive, non-self-like features found exclusively on cancer cells, effectively flagging them for the immune system. PD-1 inhibitors like Keytruda, meanwhile, function by releasing the immune system’s ‘brakes’. Together, one agent ‘points out the target’, while the other ‘releases the trigger’—enabling truly focused immune firepower. Third, it fundamentally reshapes market perception of Moderna. Following the post-pandemic decline in demand for its COVID-19 vaccines, Moderna’s stock price plunged over 90% from its 2021 peak, leading investors to reclassify the company as a ‘one-product firm’. This Phase III success, however, completely redefines its valuation logic—from ‘a vaccine seller’ to ‘a tumor-therapeutics platform company’. Bank of America raised its price target from $40 to $170, calling this milestone ‘the watershed moment marking Moderna’s transformation from an infectious-disease vaccine company into a tumor-platform company’. Piper Sandler lifted its target to $167, and Goldman Sachs to $120. The flip side of this surge was a nightmare for short sellers. According to S3 Partners, Moderna’s single-day stock surge inflicted approximately $5.5 billion in unrealized losses on short positions.

Afraid of AI stocks trading at elevated valuations? It’s time to take a closer look at Sherwin-Williams—the ‘Apple’ of the paint industry listed on U.S. exchanges (Ticker: SHW).

【Answer 2】 Among Nasdaq-100 constituents, Sherwin-Williams Company (Ticker: SHW), one of the world’s largest paint manufacturers, commands exceptional market dominance. A global leader in paint research, development, manufacturing, and distribution, Sherwin-Williams stands alongside PPG Industries as one of the two titans of the global coatings industry. Its architectural and industrial coatings businesses collectively account for over 90% of total revenue. The refined matte or metallic finishes on certain smartphone casings—and Valspar automotive touch-up paints—both originate from Sherwin-Williams’ industrial coatings portfolio. Sherwin-Williams employs a ‘company-owned retail stores + end-to-end supply-chain coverage’ business model. In the United States alone, it operates more than 4,900 company-owned stores—creating formidable industry barriers. This model mirrors Apple’s ‘Apple Store’ strategy: enabling direct access to real-time market demand while locking in premium pricing and high gross margins through brand strength. Its gross margin consistently ranges between 45% and 49%, substantially exceeding the industry average of 30%–40%. The company’s moat stems primarily from its century-and-a-half of brand equity accumulation, as well as its comprehensive, responsive logistics network—capable of delivering products to construction sites within two hours. Founded 150 years ago, this enduring enterprise went public in 1964 and is renowned on U.S. exchanges as a ‘Dividend Aristocrat’.

Bank of America Cuts Sherwin-Williams Price Target to $365.00

Apr 21, 2026

Bank of America lowered its price target for specialty chemicals firm Sherwin-Williams to $365 while maintaining a neutral rating. The company recently surpassed quarterly earnings expectations with $5.60 billion in revenue.

MarketBeat

2026-04-17

Loop Capital Adjusts Price Target on Sherwin-Williams to $385 From $400, Maintains Buy Rating

2026-04-21

Bank of America Cuts Sherwin-Williams Price Target to $365.00

2026-04-27

Concurrent Investment Advisors LLC Increases Position in Sherwin-Williams Co

2026-04-28

Sherwin-Williams Stake Reduced by Flossbach Von Storch SE

2026-04-29

Sherwin-Williams Receives 'Moderate Buy' Consensus from Analysts